Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: A randomised trial

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 130-134

  Vehreschild, J Janne ^a   Moritz, Gregor ^a   Vehreschild, Maria J G T ^a   Arenz, Dorothee ^a,b   Mahne, Martina ^b   Bredenfeld, Henning ^a   Chemnitz, Jens ^a,b   Klein, Florian ^a   Cremer, Birgit ^a   Böll, Boris ^a   Kaul, Ingrid ^b   Wassmer, Gernot ^b   Hallek, Michael ^a,b   Scheid, Christof ^a,b   Cornely, Oliver A ^a,b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Autologous transplantation; Bacteraemia; Fluoroquinolones; High dose chemotherapy; Moxifloxacin; Prophylaxis

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PLACEBO;

AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; CHOLECYSTITIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HEART ARREST; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEPSIS; VIRUS PNEUMONIA;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; BACTEREMIA; BACTERIAL INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PILOT PROJECTS; PLACEBOS; PROSPECTIVE STUDIES; QUINOLINES; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84855476630     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.10.009     Document Type: Article

References (26)

1. Link H, Blumenstengel K, Bohme A, Cornely O, Kellner O, Nowrousian MR, et al. Antimicrobial therapy for fever of unknown origin in neutropenia. Standard recommendations of the Work Group of Infections in Hematology and Oncology of the German Association of Hematology and Oncology. Dtsch Med Wochenschr 1999;124(Suppl. 1):S3-8 [in German].
2. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med 2009;360:2645-54.
3. Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008;141:3-13. (Pubitemid 351347529)
4. Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, et al. Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:186-91.
5. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl. 1):S206-15.
6. Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997;19:143-7. (Pubitemid 27068250)
7. Auner HW, Zebisch A, Ofner P, Sill H, Linkesch W, Krause R. Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases. Ann Hematol 2005;84:532-7. (Pubitemid 41001464)
8. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977-87. (Pubitemid 41262332)
9. Micozzi A, Bucaneve G. Prophylaxis and treatment of bacterial infections: do we need new strategies? Rev Clin Exp Hematol 2005;9:E4.
10. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 2006;107:1743-51. (Pubitemid 44582942)
11. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95. (Pubitemid 40840313)
12. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24: 111-8. (Pubitemid 40487379)
13. Kern WV, Steib-Bauert M, de With K, Reuter S, Bertz H, Frank U, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother 2005;55:57-60. (Pubitemid 40192614)
14. Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 2005;24:832-8. (Pubitemid 43042790)
15. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721-8. (Pubitemid 351321152)
16. Carratalá J, Fernández-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60 [discussion 561-563].
17. Carratala J, Fernandez-Sevilla A, Tubau F, Dominguez MA, Gudiol F. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996;40:503-5. (Pubitemid 26049371)
18. Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer 2003;97:419-24. (Pubitemid 36133809)
19. von Baum H, Sigge A, Bommer M, Kern WV, Marre R, Dohner H, et al. Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 2006;58:891-4. (Pubitemid 44390974)
20. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005;353:988-98. (Pubitemid 41262333)
21. Hardy D, Amsterdam D, Mandell LA, Rotstein C. Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. Antimicrob Agents Chemother 2000;44:802-5. (Pubitemid 30117988)
22. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
23. Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol 2005;130:265-70. (Pubitemid 41602527)
24. Reich G, Mapara MY, Reichardt P, Dorken B, Maschmeyer G. Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors. Bone Marrow Transplant 2001;27:525-9. (Pubitemid 32266503)
25. Blondeau JM, Laskowski R, Bjarnason J, Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50. (Pubitemid 30136401)
26. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2007;59:5-22. (Pubitemid 46017895)